## AMGN: Amgen Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -5.8% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($305.31)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Has the Market Fully Priced In Amgenâ€™s Rally After Pipeline and Regulatory Milestones?**
- Source: Simply Wall Street | 20251207T030903 | Somewhat-Bullish | Relevance: 100%
-  Amgen's stock has seen significant gains, up 27.2% year to date, fueled by an expanding pipeline and regulatory milestones. Analysis using Discounted Cash Flow and Price vs. Earnings models suggests Amgen is currently undervalued. The article presents bullish and bearish narratives for Amgen, with fair value estimates ranging from $322.88 to $404.87 per share.

**2. Gabelli Funds LLC Sells 3,150 Shares of Amgen Inc. $AMGN**
- Source: MarketBeat | 20251208T114955 | Somewhat-Bullish | Relevance: 99%
-  Gabelli Funds LLC reduced its stake in Amgen Inc. by 4.8% in the second quarter, selling 3,150 shares and retaining 62,900 shares valued at $17,562,000. Despite this, other institutional investors like Vanguard Group Inc., Geode Capital Management LLC, and Charles Schwab Investment Management Inc. increased their positions in the medical research company. Amgen recently reported strong quarterly earnings, surpassing analyst expectations, and declared a quarterly dividend of $2.38 per share.

**3. Amgen Inc. $AMGN Shares Sold by California Public Employees Retirement System**
- Source: MarketBeat | 20251207T090937 | Bullish | Relevance: 99%
-  California Public Employees Retirement System reduced its stake in Amgen Inc. by 0.4%, selling 9,206 shares. Despite this, Amgen (NASDAQ:AMGN) reported strong Q2 earnings, beating analyst expectations for both EPS and revenue, and announced a quarterly dividend of $2.38 per share. Several other institutional investors adjusted their positions in Amgen, and Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $335.65 for the stock.

**4. Amgen Inc.'s (NASDAQ:AMGN) Intrinsic Value Is Potentially 68% Above Its Share Price**
- Source: Yahoo Finance | 20251207T120937 | Bullish | Relevance: 99%
-  According to Simply Wall St's analysis, Amgen Inc. (NASDAQ:AMGN) appears significantly undervalued with an estimated intrinsic value of US$554, which is 68% above its current share price of US$330. The analysis uses a 2-stage Discounted Cash Flow (DCF) model and suggests a potential 40% undervaluation. However, it's noted that the analyst price target for AMGN is US$324, indicating a discrepancy with Simply Wall St's fair value estimate.

**5. Amgen Inc. $AMGN Shares Purchased by Daiwa Securities Group Inc.**
- Source: MarketBeat | 20251209T103052 | Somewhat-Bullish | Relevance: 98%
-  Daiwa Securities Group Inc. has increased its holdings in Amgen Inc. by 5.1% in the second quarter, bringing its total ownership to 229,666 shares valued at $64.125 million. Several other hedge funds also adjusted their stakes in Amgen, while some corporate insiders sold shares. Wall Street analysts have issued mixed ratings for Amgen, with a consensus "Moderate Buy" and an average target price of $335.65.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-03 | BMO Capital | $372 | $335 | +11% |
| 2025-11-14 | Piper Sandler | $381 | $342 | +11% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-03 | BMO Capital | main | Outperform |
| 2025-11-14 | Piper Sandler | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($0.00M) |
| Sells | 7 ($2.74M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.3%)
- Blackrock Inc.: 8.6% (-1.2%)
- State Street Corpora: 5.4% (-0.2%)
- Capital Internationa: 3.6% (+1.5%)
- Capital World Invest: 3.5% (+11.5%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-3.1% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Forward P/E 14.7x stretched relative to 3% growth. Quality metrics strong (ROE 82%, margin 20%). Balance sheet: $4.2B free cash flow. Analyst sentiment positive (2 raises, avg +11%). Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $173.0B |
| Beta | 0.45 |
| 52W Range | $253.30 - $346.38 |
| Short Interest | 2.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 14.7 |
| Current P/E | 15.1 |
| YoY Growth | 2.9% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -2.7% to -5.8% (-3.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.8pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.08x) but short-term weakness (below SMA20). MACD histogram bearish (-3.13), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -5.81% (CS: 4) | Weak |
| RSI_14 | 44.4 | Neutral |
| MACD Histogram | -3.13 | Bearish |
| vs SMA20 | 0.952x | Below |
| vs SMA50 | 1.026x | Above |
| vs SMA200 | 1.082x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $321.23
- **Stop Loss:** $305.31 (5.0% risk)
- **Target:** $337.15 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 31
- **Position Value:** $9,958.13
- **Portfolio %:** 9.96%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-03 (Est: $4.74)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.01 | $5.64 | +12.5% |
| 2025Q2 | $5.28 | $6.02 | +14.1% |
| 2025Q1 | $4.26 | $4.90 | +15.0% |
| 2024Q4 | $5.08 | $5.31 | +4.6% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_10*